Hospital
Medical University Hospital Authority
Medical University Hospital Authority was paid $4.66M by Medicaid between Aug 2021 and Dec 2024, across 130 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 19% of everything it billed.
33Billing provider infoMEDICAL UNIVERSITY HOSPITAL AUTHORITY
COLUMBIA, SC 29203
COLUMBIA, SC 29203
33aNPI1285200105assigned 06/01/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.66M
24GClaims173,139
24DCodes billed130
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#51 of 115
Median peer was paid$2.47M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 25,309 | $933K | |
| 2022 | 51,413 | $1.38M | |
| 2023 | 53,684 | $1.36M | |
| 2024incomplete | 42,733 | $996K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 19% | 9,031 | 8,094 | $894K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 7,241 | 6,810 | $595K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 12% | 5,588 | 5,325 | $547K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9.0% | 3,730 | 2,831 | $418K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.9% | 2,762 | 2,456 | $230K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.9% | 306 | 223 | $229K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.4% | 12,929 | 12,041 | $158K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 2,143 | 1,918 | $126K |
| 36415 | Collection of venous blood by venipuncture | 2.5% | 10,802 | 9,259 | $118K |
| 81003 | 2.1% | 4,389 | 3,958 | $99K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,092 | 1,929 | $86K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 3,238 | 2,910 | $64K |
118 more codes
| 81025 | 1.2% | 4,776 | $57K | |
| 87210 | 1.2% | 614 | $56K | |
| 87430 | 1.1% | 477 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 1,304 | $47K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,554 | $46K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 236 | $44K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,060 | $42K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 201 | $37K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,480 | $37K |
| 73630 | <1% | 477 | $35K | |
| 81001 | <1% | 4,189 | $35K | |
| 73130 | <1% | 375 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 282 | $34K |
| 73560 | <1% | 781 | $33K | |
| 99284 | Emergency room visit (serious) | <1% | 7,283 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,372 | $32K |
| 73610 | <1% | 359 | $32K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 427 | $28K |
| 84702 | <1% | 692 | $27K | |
| 73030 | <1% | 419 | $26K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,493 | $25K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 685 | $25K |
| 99285 | Emergency room visit (most serious) | <1% | 2,286 | $18K |
| 72100 | <1% | 465 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 507 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,090 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,682 | $16K |
| 86900 | <1% | 90 | $14K | |
| 97597 | <1% | 228 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 96 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,938 | $13K |
| 73110 | <1% | 115 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 918 | $12K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 83 | $11K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 12 | $11K |
| 82947 | <1% | 771 | $8K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,886 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 602 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 285 | $7K |
| 88304 | <1% | 149 | $6K | |
| 87077 | <1% | 129 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 178 | $5K |
| 72040 | <1% | 76 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 462 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,650 | $3K |
| 74018 | <1% | 27 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 675 | $3K |
| 86140 | <1% | 84 | $3K | |
| 87420 | <1% | 67 | $2K | |
| 10060 | <1% | 15 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 246 | $2K |
| 82962 | <1% | 35 | $2K | |
| 83690 | <1% | 3,322 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 240 | $1K |
| 84484 | <1% | 3,829 | $1K | |
| 73502 | <1% | 25 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 107 | $1K |
| A9270 | Non-covered item or service | <1% | 2,137 | $1K |
| 93971 | <1% | 64 | $1K | |
| 85379 | <1% | 1,354 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $916.42 |
| 83735 | <1% | 3,318 | $837.52 | |
| 73590 | <1% | 15 | $774.79 | |
| 84703 | <1% | 719 | $765.13 | |
| 85027 | <1% | 755 | $758.79 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 773 | $736.21 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,733 | $624.02 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 631 | $434.49 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 102 | $426.84 |
| 83880 | <1% | 769 | $404.16 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,148 | $376.73 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,002 | $297.00 |
| G0378 | Hospital observation service, per hour | <1% | 155 | $235.85 |
| 85610 | <1% | 371 | $215.38 | |
| 87081 | <1% | 437 | $200.23 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,281 | $132.92 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,646 | $46.87 |
| 83605 | <1% | 237 | $43.60 | |
| 96376 | <1% | 578 | $41.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,445 | $29.85 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,748 | $28.47 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,322 | $22.26 |
| 84100 | <1% | 40 | $12.83 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 184 | $5.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,486 | $5.27 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 317 | $1.87 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,448 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 891 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 153 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 186 | $0.00 |
| 82077 | 0% | 12 | $0.00 | |
| 87040 | 0% | 73 | $0.00 | |
| 86901 | 0% | 90 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 255 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 45 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 69 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 39 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 62 | $0.00 |
| 85730 | 0% | 44 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 162 | $0.00 |
| 94644 | 0% | 14 | $0.00 | |
| 80320 | 0% | 15 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 38 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 17 | $0.00 |
| 85651 | 0% | 16 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 363 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 807 | $0.00 |
| 90715 | 0% | 75 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 21 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 61 | $0.00 |
| 87631 | 0% | 16 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 32 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 57 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 37 | $0.00 |
| 87186 | 0% | 53 | $0.00 | |
| 80076 | 0% | 23 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAE, KARYN (CHIEF)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.